Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 9:10 a.m. ET and Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 10:40 a.m. ET.
According to the company, sessions are accessible via its Investors & Media page, with replays and transcripts archived on the website for at least 30 days.
Regeneron (NASDAQ: REGN) will present 36 abstracts at AAAAI 2026 (Feb 27–Mar 2), including first Phase 3 allergen-challenge results for investigational antibody cocktails targeting cat (Fel d 1) and birch (Bet v 1) allergies and multiple new Dupixent® (dupilumab) analyses across pediatric allergy sensitization, asthma, CRSwNP and EoE.
Regeneron said additional registration-enabling trials for the cat and birch programs will start in 2026, and a Dupixent supplemental BLA for AFRS is under Priority Review with a target action date of Feb 28, 2026.
Regeneron (NASDAQ: REGN) will present new clinical data for EYLEA HD (aflibercept) 8 mg at the virtual Angiogenesis meeting on February 7, 2026. Presentations include final 64-week QUASAR results in retinal vein occlusion (RVO) and full primary Phase 3b ELARA data for monthly dosing.
FDA recently approved EYLEA HD for macular edema following RVO; QUASAR met its 36-week primary endpoint and offers the first every-two-month treatment option versus prior monthly dosing. ELARA supports a monthly option for patients needing more frequent treatment. Common adverse reactions (≥3%) are listed in the safety data.
Regeneron (NASDAQ: REGN) reported Q4 2025 revenues of $3.884B (up 3% YoY) and full-year 2025 revenues of $14.343B (up 1% YoY). Q4 GAAP EPS was $7.86 and non-GAAP EPS was $11.44. Key commercial drivers included strong Dupixent and EYLEA HD performance and increased Sanofi collaboration revenue.
Regeneron secured multiple regulatory approvals for EYLEA HD, Dupixent and Libtayo and filed BLAs/NDAs for programs including DB-OTO and garetosmab. The company plans substantial manufacturing and R&D investments in 2026.
Regeneron (NASDAQ: REGN) and Society for Science named the top 40 finalists for the Regeneron Science Talent Search 2026, representing 35 schools across 15 states and competing for more than $1.8 million in awards, including a $250,000 top prize. Finalists were selected from 300 scholars and more than 2,600 entrants based on original research. Finalists will compete March 5-11, 2026, with a public project exhibition on March 8 and winners announced March 10 in Washington, D.C. Regeneron noted its 10-year $100 million commitment and an expanded annual award distribution now totaling $3.1 million.
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
The company will host a conference call and simultaneous webcast on January 30, 2026 at 8:30 AM Eastern Time. Investors may join the live webcast via Regeneron’s Investors and Media web page or register in advance to participate by telephone and receive dial-in details, a unique passcode, and registrant ID.
A replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) and Sanofi announced that Japan's Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for children aged 6 to 11 years with severe or refractory bronchial asthma inadequately controlled by existing therapy, expanding prior approval for ages 12 and up.
Approval was supported by the global Phase 3 VOYAGE program and the EXCURSION extension, where Dupixent added to standard care reduced severe exacerbations 54%–65% and improved lung function 4.68%–5.32% versus placebo; a Japanese pediatric sub-study showed improved lung function at 12 weeks and low annual exacerbation rates.
Regeneron (NASDAQ: REGN) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
The live webcast is scheduled for 2:15 p.m. Pacific Time / 5:15 p.m. Eastern Time and can be accessed from the company’s Investors & Media page at http://investor.regeneron.com/events-and-presentations. A replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) reported encouraging Phase 1/2 LINKER-MM4 data for Lynozyfic (linvoseltamab) monotherapy in newly diagnosed multiple myeloma presented at ASH on Dec 7, 2025. Across 45 treated patients (50/100/200 mg), median time to response was 1.2 months and all dose groups achieved VGPR+ ≥70% with limited follow-up. Of 20 MRD-evaluable VGPR+ patients, 95% (19 of 20) were MRD negative at 10-5 sensitivity. Common TEAEs included CRS (all Grade 1) 44%, neutropenia any Grade 38% (Grade 3/4 33%), and infections in 84% (Grade 3 33%). No Grade 5 TEAEs or dose-limiting toxicities were reported.
The program will continue with a Phase 2 expansion and combination studies in earlier lines.
Regeneron (NASDAQ:REGN) and Tessera Therapeutics announced a global collaboration to develop TSRA-196, an investigational one-time gene editing therapy for alpha-1 antitrypsin deficiency (AATD).
Key points: Tessera will receive $150 million (cash upfront plus equity) and is eligible for $125 million in near/mid-term milestones; the companies will share development costs and future profits 50:50. Tessera expects to file an IND and CTA submissions by year-end. Preclinical data showed durable SERPINA1 editing in mice and non-human primates with high liver specificity and no off-target signal reported. The agreement is subject to customary closing conditions, including HSR antitrust clearance.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
